Impact of adjunct bezlotoxumab for preventing Clostridioides difficile infection recurrence in patients post – hematopoietic stem cell transplantation
Journal of Oncology Pharmacy Practice
Published online on January 27, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundPatients post hematopoietic stem cell transplant (HSCT) are highly susceptible toClostridioides difficileinfection (CDI). Exposure to antibiotic treatment, chemotherapeutic disruption to bacterial microbiome, immunosuppressive therapy, and ...
BackgroundPatients post hematopoietic stem cell transplant (HSCT) are highly susceptible toClostridioides difficileinfection (CDI). Exposure to antibiotic treatment, chemotherapeutic disruption to bacterial microbiome, immunosuppressive therapy, and ...